The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $16.00 in the prior trading day, Denali Therapeutics Inc (NASDAQ: DNLI) closed at $15.99, down -0.06%. In other words, the price has decreased by $-0.06 from its previous closing price. On the day, 3.06 million shares were traded. DNLI stock price reached its highest trading level at $16.28 during the session, while it also had its lowest trading level at $15.48.
Ratios:
Our goal is to gain a better understanding of DNLI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.65 and its Current Ratio is at 13.65. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on December 13, 2023, initiated with a Buy rating and assigned the stock a target price of $32.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 15 ’24 when SATO VICKI L sold 1,666 shares for $18.29 per share. The transaction valued at 30,471 led to the insider holds 118,043 shares of the business.
Krognes Steve E. sold 92,500 shares of DNLI for $1,896,250 on Apr 01 ’24. The Director now owns 47,341 shares after completing the transaction at $20.50 per share. On Mar 15 ’24, another insider, SATO VICKI L, who serves as the Director of the company, sold 1,666 shares for $20.10 each. As a result, the insider received 33,487 and left with 119,709 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNLI now has a Market Capitalization of 2279214592 and an Enterprise Value of 1244293888. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.73 while its Price-to-Book (P/B) ratio in mrq is 2.15. Its current Enterprise Value per Revenue stands at 3.765 whereas that against EBITDA is -6.623.
Stock Price History:
Over the past 52 weeks, DNLI has reached a high of $33.31, while it has fallen to a 52-week low of $15.45. The 50-Day Moving Average of the stock is -16.60%, while the 200-Day Moving Average is calculated to be -24.02%.
Shares Statistics:
The stock has traded on average 1.19M shares per day over the past 3-months and 1107590 shares per day over the last 10 days, according to various share statistics. A total of 138.39M shares are outstanding, with a floating share count of 112.30M. Insiders hold about 19.31% of the company’s shares, while institutions hold 78.45% stake in the company. Shares short for DNLI as of 1711584000 were 9414755 with a Short Ratio of 7.89, compared to 1709164800 on 8866037. Therefore, it implies a Short% of Shares Outstanding of 9414755 and a Short% of Float of 8.02.
Earnings Estimates
Denali Therapeutics Inc (DNLI) is currently under the scrutiny of Dragonfly Energy Holdings Corp analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $15.99, with high estimates of $22.35 and low estimates of $37.40.
